aXichem AB Class A (SE:AXIC.A)
:AXIC.A
Top Page
aXichem AB Class A
(AXIC.A)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr2.00
▼(-6.98% Downside)
Action:ReiteratedDate:01/21/26
The score is primarily held back by weak financial performance: large ongoing losses and persistent cash burn despite improving revenue and strong gross margins. Technicals also weigh on the score, with the stock below all major moving averages and negative MACD. Valuation is only moderately supportive because a negative P/E reflects ongoing losses and dividend yield is not available.
Positive Factors
High gross margins
An ~83% gross margin indicates the product technology commands strong per-unit economics in specialty chemical/animal nutrition end-markets. High gross margins create durable opportunity for operating leverage as revenue scales, improving the pathway to sustained profitability if SG&A and R&D are controlled.
Negative Factors
Deep and persistent unprofitability
A net margin near -208% and negative EBIT/EBITDA reflect a cost base far exceeding current revenues. Absent rapid revenue scale or cost restructuring, persistent losses can erode equity, limit reinvestment capacity, and force dilutive financings, threatening long-term viability if profitability remains out of reach.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
An ~83% gross margin indicates the product technology commands strong per-unit economics in specialty chemical/animal nutrition end-markets. High gross margins create durable opportunity for operating leverage as revenue scales, improving the pathway to sustained profitability if SG&A and R&D are controlled.
Read all positive factors
aXichem AB Class A (AXIC.A) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr102.27M
Dividend YieldN/A
Average Volume (3M)26.22K
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue Growth114.57%
EPS Growth53.86%
CountrySE
Employees7
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.25
Shares Outstanding67,729,120
10 Day Avg. Volume21,219
30 Day Avg. Volume26,221
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.89
Price to Sales (P/S)7.31
P/FCF Ratio-5.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.14
Revenue Forecast (FY)kr53.80M
aXichem AB Class A Business Overview & Revenue Model
Company Description
aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, an natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antif...
How the Company Makes Money
aXichem AB generates revenue primarily by selling its synthetic capsaicin products to companies operating in the health, feed, and food industries. The company's key revenue streams include direct sales of its products to manufacturers who incorpo...
aXichem AB Class A Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.93M | 8.57M | 1.81M | 5.01M | 4.36M | 1.23M |
| Gross Profit | 7.06M | 7.08M | 1.41M | 3.82M | 909.00K | 596.00K |
| EBITDA | -15.10M | -11.55M | -15.10M | -12.44M | -13.49M | -12.01M |
| Net Income | -20.51M | -17.81M | -20.81M | -17.26M | -15.09M | -13.52M |
Balance Sheet | ||||||
| Total Assets | 68.18M | 74.28M | 61.49M | 61.25M | 58.77M | 55.75M |
| Cash, Cash Equivalents and Short-Term Investments | 6.78M | 14.36M | 4.31M | 6.55M | 9.45M | 12.04M |
| Total Debt | 3.09M | 0.00 | 10.27M | 18.76M | 0.00 | 0.00 |
| Total Liabilities | 7.13M | 4.13M | 12.96M | 20.92M | 2.47M | 2.10M |
| Stockholders Equity | 61.02M | 70.13M | 48.51M | 40.31M | 56.30M | 53.65M |
Cash Flow | ||||||
| Free Cash Flow | -10.94M | -11.50M | -15.68M | -21.71M | -20.32M | -18.93M |
| Operating Cash Flow | -10.94M | -11.50M | -15.68M | -19.10M | -15.60M | -11.69M |
| Investing Cash Flow | -6.63M | -6.50M | -5.10M | -2.61M | -4.73M | -7.23M |
| Financing Cash Flow | 14.32M | 28.05M | 18.54M | 18.80M | 17.73M | 0.00 |
aXichem AB Class A Technical Analysis
Neutral
2.15
Price Trends
1.48
Positive
1.92
Negative
2.43
Negative
Market Momentum
0.03
Negative
58.21
Neutral
43.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:AXIC.A, the sentiment is Neutral. The current price of 2.15 is above the 20-day moving average (MA) of 1.35, above the 50-day MA of 1.48, and below the 200-day MA of 2.43, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 58.21 is Neutral, neither overbought nor oversold. The STOCH value of 43.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:AXIC.A.
aXichem AB Class A Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
55 Neutral | kr302.36M | -12.04 | -9.48% | ― | -1.89% | -59.17% | |
47 Neutral | kr39.35M | -1.42 | -75.93% | 0.00% | ― | ― | |
44 Neutral | kr102.27M | -6.99 | -29.85% | ― | 114.57% | 53.86% | |
44 Neutral | kr56.20M | -5.87 | ― | ― | ― | ― | |
42 Neutral | kr145.20M | -4.90 | -153.91% | ― | -18.29% | -48.74% |
* Basic Materials Sector Average
SE:AXIC.A
aXichem AB Class A
1.51
0.27
22.27%
SE:NEXAM
Nexam Chemical Holding AB
2.95
-0.23
-7.23%
SE:AERO
Svenska Aerogel Holding AB
1.35
-0.87
-39.19%
SE:ORGC
OrganoClick AB
1.32
-0.92
-41.05%
SE:XPC
XP Chemistries AB
0.18
0.07
58.41%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.